


Benin

Region: #N/A

Key information on co-financing

- Gross National Income per capita (2017): \$ 860
- Co-financing status (2019): Initial self-financing
 Country is projected to enter preparatory transition phase in
- Country is projected to enter preparatory transition phase in 2021.



Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 1,834,976 \$	1,833,584 \$	1,834,977 \$	3,685,251 \$	1,914,299
- Total expenditure	\$ 5,680,819 \$	5,676,510 \$	4,152,092 \$	11,887,905 \$	3,632,233
- Government as % of total	32%	32%	44%	31%	53%
Routine immunisation					
 Government expenditure 	\$ 2,116,104 \$	2,114,499 \$	1,717,158 \$	3,951,102 \$	2,653,336
 Total expenditure 	\$ 6,366,843 \$	6,362,014 \$	5,203,510 \$	11,887,905 \$	5,049,853
- Government as % of total	33%	33%	33%	33%	53%


Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product:

0.6%

Source: WHO National Health Accounts, 2015

Expenditure on routine immunisation in 2017



Gavi supported vaccines

Vaccines	Туре	Year(s) of Gavi support	Co-financing required
HepB mono	Routine	2001 - 2005	No
Pentavalent	Routine	2005 - present	Yes
Yellow Fever	Routine	2002 - present	Yes
Yellow Fever	Campaign	2009	No
PCV	Routine	2011 - present	Yes
MenA	Campaign	2012	No
IPV	Routine	2015 - present	No
HPV	Demonstration	2016 - 2017	No
MR	Routine	2018 - present	Yes

Country started co-financing form 2008.


Co-financing payments

	Tota	l amount paid by the country	Co-fina	anced vaccines			
2008	\$	213,000	YF				
2009	\$	105,000	YF				
2010	\$	328,000	YF	Penta			
2011	\$	415,000	YF	Penta			
2012	\$	542,000	YF	Penta			
2013	\$	692,000	YF	Penta			
2014	\$	650,000	YF	Penta	PCV		
2015	\$	388,000	YF	Penta	PCV		
2016	\$	521,000	YF	Penta	PCV		
2017	\$	470,000	YF	Penta	PCV		
2018	\$	789,000	YF	Penta	PCV	MR	

Co-financing obligations for 2019

	Co-financing obligations		Co-financing obligations	
	(in US\$)		(in doses)	
Pentavalent	\$	219,000		308,000
PCV	\$	233,000		78,200
YF	\$	79,500		64,800
MR	\$	112,000		171,900
Rota	\$	154,500		162,700
Total	\$	798,000		

Co-financing projections for 2020 - 2024



	2020		2021	2022		2023		2024	
Penta	\$	198,159	\$ 205,565	\$	118,827	\$	139,058	\$	162,473
PCV	\$	211,497	\$ 219,401	\$	542,344	\$	634,397	\$	741,586
Rota	\$	70,301	\$ 145,106	\$	248,894	\$	289,591	\$	338,511
MR routine	\$	225,970	\$ 220,037	\$	360,897	\$	398,007	\$	465,249
YF routine	\$	82,789	\$ 85,060	\$	84,113	\$	98,380	\$	115,031
Total	\$	788,717	\$ 875,168	\$	1,355,075	\$	1,559,433	\$	1,822,850

- Projections are based on Gavi's operational forecast version 16.
- Country is approved for Rota introduction in 2019.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.